Living with mesothelioma. A literature review

European Journal of Cancer Care

Volumn 19, Issue 4, 2010, Pages 458-468

  Moore, S ^a   Darlison, L ^b   Tod, A M ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Cancer; Mesothelioma; Patient carer experience

Indexed keywords

CAREGIVER; FAMILY; HEALTH CARE DELIVERY; HUMAN; LUNG TUMOR; MESOTHELIOMA; METHODOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; STANDARD;

CAREGIVERS; DELIVERY OF HEALTH CARE; FAMILY; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; QUALITY OF LIFE;

EID: 77954773610     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2009.01162.x     Document Type: Review

References (34)

1. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. Journal of Clinical Oncology 1988, 6:147-153.
2. Bakwaj S, Lee B. Case 23. Difficult pain in a patient with mesothelioma. European Journal of Palliative Care 2005, 12:237-238.
3. Bottomley A, Gaafa R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, van Meerbeeck J. Short-term treatment-related symptoms and quality of life: results from an international randomised phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Cananda, Intergroup study. Journal of Clinical Oncology 2006, 24:1435-1442.
4. Bottomley A, Coens C, Eficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeck JP. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2008, 25:5770-5776.
5. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. European Respiratory. Journal 1998, 12:972-981.
6. Survey of Mesothelioma Patients and their Carers http://www.lunguk.org/Resources/British%20Lung%20Foundation/Survey%20of%20mesothelioma%20patients%20and%20their%20carers%20FINAL%20(complete).pdf, British Lung Foundation (BLF), BLF, London, Available at: (8/3/09
7. Statement on Malignant Mesothelioma in the UK 2007, British Thoracic Society, British Thoracic Society, London
8. UK Cancer incidence statistics for common cancers. 2007, http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/?a=5441, Cancer Research UK, Available at: (01/02/09
9. UK Cancer mortality statistics for common cancers. 2008, http://info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/, Cancer Research UK, Available at: (01/02/09
10. Chahinian AP, Thomas MD, Pajak F, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Annals of Internal Medicine 1982, 96:746-755.
11. Chapman E, Hughes D, Landy A, Whale J, Saunders M. Challenging the respresentations of cancer pain: experiences of a multidisciplinary pain management group in a palliative care unit. Palliative & Supportive Care 2005, 3:43-49.
12. Clayson H, Seymour J, Noble B. Mesothelioma from the patient's perspective. Hematology Oncology Clinics of North America 2005, 19:1175-1190.
13. Curran D, Sahmoud T, Therasse P, Van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organisation for Research and Treatment of Cancer experience. Journal of Clinical Oncology 1998, 16:145-152.
14. De Klerk NH, Musk AW. Epidemiology of mesothelioma. Mesothelioma 2002, 39-50. Robinson BW, Chahinian PA. eds, Martin Dunitz, London
15. Mesothelioma Framework: Advice for the NHS on How to Organise Services for Malignant Pleural Mesothelioma (MPM) Patients to Improve Quality of Care across the Country 2007, Department of Health (DOH), Gateway ref: 7907, DOH, London
16. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000, 55:731-735.
17. Foss C, Ellefsen B. The value of combining qualitative and quantitative approaches in nursing research by means of method triangulation. Journal of Advanced Nursing 2002, 40:242-248.
18. Hawley R, Monk A, Wiltshire J. The mesothelioma journey. 2004, Unpublished report. University of Sydney
19. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723-731.
20. Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma. Cancer 2004, 101:587-595.
21. Hughes N, Arber A. The lived experience of patients with pleural mesothelioma. International Journal of Palliative Nursing 2008, 14:66-71.
22. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995, 108:1122-1128. International Mesothelioma Interest Group (IMIG)
23. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005, 49:53-58.
24. Lebovits AH, Chahinian AP, Gorzynski JG, Holland JC. Psychological aspects of asbestos-related meosthelioma and knowledge of high risk for cancer. Cancer Detection and Prevention 1981, 4:181-184.
25. Lebovits AH, Chahinian AP, Holland JC. Exposure to asbestos: psychological responses of mesothelioma patients. American Journal of Industrial Medicine 1983, 4:459-466.
26. Montanaro F, Bray F, Gennaro V, Merler E, Tyczynski JE, Parkin DM. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes and Control 2003, 14:791-803.
27. Moore S, Teehan C, Cornwall A, Ball K, Thomas J. 'Hands of Time': the experience of establishing a support group for people affected by mesothelioma. European Journal of Cancer Care 2008, 17:585-592.
28. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CMB, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MKB. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371:1685-1694.
29. Lung Cancer Research in the UK 2006, National Cancer Research Institute (NCRI), London, NCRI
30. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity and results of using the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. Journal of Clinical Oncology 2004, 22:3172-3180.
31. O'Brien MER, Watkins D, Ryan C, Priest K, Corbishley C, Norton A, Ashley S, Rowell N, Sayer R. A randomised trail in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Annals of Oncology 2006, 17:270-275.
32. O'Byrne KJ, Edwards JG, Waller DA. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 2004, 45:S45-48.
33. Patel SN, Kettner NW. Malignant pleural mesothelioma: a case report. Journal of Manipulative and Physiological Therapeutics 2005, 28:724-729.
34. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, Ayoub J, Shepherd F, Evans WK, Figuerdo A, Pater JL, Pringle JF, Kreisman H. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. Journal of Clinical Oncology 1989, 7:1157-1168.